Medindia

X

Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth

Thursday, July 10, 2008 General News J E 4
Advertisement
ANTONY, France, July 10

- 1st Half-Year Sales Up 16%

2008 second quarter sales recorded strong growth in all markets (+18% vs+13% in 2007). Eastern European markets and other markets outside Europe madea significant contribution to this growth. The most buoyant segment of themarket remained desensitisation via the sublingual route (SLIT, +21%, vs +15%in 2007) whose reputation was enhanced by the launch of allergen tablets.

Cumulated sales for the first half-year increased by 16% compared to thefirst half 2007, when growth was already particularly strong (+ 17%). Thisgood performance has enabled the Group to revise its sales growth guidanceupwards to growth of at least 12% in 2008 (vs (greater than or equal to)10%previously), boosted by the growing success of the sublingual route, in whichStallergenes continues to strengthen its leadership.

The commercial launch of ORALAIR(R) Grasses for adults will take place inGermany in the next few weeks, following the grant, on 24 June 2008, of themarketing authorisation. The request for a paediatric extension of ORALAIR(R)Grasses has been filed with the Paul Ehrlich Institute. The application forclinical studies for ORALAIR(R) Grasses in the US will be filed in July.

The 2008 first half-year financial results will benefit from a stronglevel of activity and will show a marked improvement compared to 2007. Theseresults will be released on 27 August 2008.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated todesensitisation therapies for the prevention and treatment of allergy-relatedrespiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. Apioneer and leader in sublingual desensitisation treatment, Stallergenesdevotes 16% of its turnover to Research and Development and is activelyinvolved in the development of a new therapeutic class: sublingualdesensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provideddesensitisation treatments to more than 500,000 patients.- Revision Upwards of 2008 Sales Growth Guidance: (greater than or equalto)12% EUR millions 2006 2007 07/06 2008 08/07 EURM %Sales EURM %Sales % EURM %Sales % change change Southern Europe (1) 20.5 72 23.2 72 13 26.8 71 15 Other EU countries (2) 6.9 24 7.7 24 11 9.3 24 20 Other markets 1.2 4 1.3 4 15 2.0 5 47 SLIT 21.8 76 25.1 77 15 30.4 80 21 SCIT 5.4 19 5.6 18 5 6.1 16 7 Other products 1.5 5 1.5 5 (0) 1.6 4 4 Total Q2 sales 28.6 100 32.2 100 13 38.0 100 18 Southern Europe (1) 48.1 75 56.5 76 18 64.7 75 14 Other EU countries (2) 13.7 21 15.8 21 15 18.6 21 18 Other markets 2.4 4 2.5 3 5 3.7 4 46 SLIT 49.4 77 59.7 80 21 71.3 82 19 SCIT 11.6 18 11.8 16 2 12.3 14 4 Other products 3.2 5 3.2 4 3 3.4 4 6 Total H1 sales 64.2 100 74.8 100 17 87.0 100 16 (1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

SOURCE Stallergenes
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Eisai Renews Its Commitment to Responsible Healthc...
S
Statement on CDC Announcement That 70 Percent of t...